Effects of pravastatin and cholestyramine on products of the mevalonate pathway in familial hypercholesterolemia.

This publication has 22 references indexed in Scilit:

• Treatment of familial hypercholesterolaemia: a controlled trial of the effects of pravastatin or cholestyramine therapy on lipoprotein and apolipoprotein levels
  Journal of Internal Medicine, 1990
• Influence of Pravastatin, a Specific Inhibitor of HMG-CoA Reductase, on Hepatic Metabolism of Cholesterol
  New England Journal of Medicine, 1990
• Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia
  The Lancet, 1990
• Regulation of the mevalonate pathway
  Nature, 1990
• Conditions for Quantitation of Dolichyl Phosphate, Dolichol, Ubiquinone and Cholesterol by HPLC
  Biomedical Chromatography, 1989
• Determination of serum levels of unesterified lathosterol by isotope dilution-mass spectrometry
  Scandinavian Journal of Clinical and Laboratory Investigation, 1989
• In vitro and in vivo synthesis of dolichol and other main mevalonate products in various organs of the rat
  European Journal of Biochemistry, 1987
• Plasma mevalonate as a measure of cholesterol synthesis in man.
  Journal of Clinical Investigation, 1984
• Effects of an Inhibitor of 3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase on Serum Lipoproteins and Ubiquinone-10 Levels in Patients with Familial Hypercholesterolemia
  New England Journal of Medicine, 1981
• (R)-mevalonate excretion in human and rat urines.
  Proceedings of the National Academy of Sciences, 1980